Skip to main content
SpringerLink
Log in

Efficacy of low dose hCG on oocyte maturity for ovarian stimulation in poor responder women undergoing intracytoplasmic sperm injection cycle: a randomized controlled trial

  • ASSISTED REPRODUCTION TECHNOLOGIES
  • Published:
Journal of Assisted Reproduction and Genetics Aims and scope Submit manuscript

Abstract

Purpose

To investigate the effect of late follicular administration of low dose hCG on oocyte maturity in poor responding women undergoing intracytoplasmic sperm injection (ICSI).

Materials and methods

This prospective randomized pilot trial was performed on 73 poor responders undergoing ICSI, in Reproductive Biomedicine Research Center, Royan Institute, Tehran, Iran. All eligible patients underwent a GnRH-a long protocol and were randomly allocated into three study groups for ovarian stimulation: groupA received recombinant FSH alone, group B received recombinant FSH supplemented by 100 IU hCG. Group C received recombinant FSH supplemented by 200 IU hCG. The main endpoint was the number of metaphase II oocytes retrieved.

Results

Of 78 poor responding patients entered to this study, 73 women were considered eligible for enrolment. Of these, 26 women were allocated to receive only recombinant FSH, 24 patients allocated to receive recombinant FSH and 100 IU hCG and 23 patients were assigned to receive recombinant FSH and 200 IU hCG. Number of oocytes retrieved were significantly higher in group B compared to group A (6.5 ± 3.3 versus 4.0 ± 2.3; P = .03). Other cycle and clinical outcomes were comparable between three groups.

Conclusions

The present study demonstrated that adding 100 IU hCG to rFSH in a GnRH agonist cycle in poor responders improve response to stimulation whereas the number of metaphase II oocytes remains comparable between groups. The existence of a possible trend toward higher mature oocytes and lower total dosage rFSH in patients received 100 or 200 IU hCG is probably due to the small sample size that means further large clinical trials in a more homogenous population is required (clinical trial registration number; NCT01509833).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Keay SD, Liversedge NH, Mathur RS, Jenkins JM. Assisted conception following poor ovarian response to gonadotrophin stimulation. Br J Obstet Gynaecol. 1997;104(5):521–7.

    Article  PubMed  CAS  Google Scholar 

  2. Pellicer A, Lightman A, Diamond MP, Russell JB, DeCherney AH. Outcome of in vitro fertilization in women with low response to ovarian stimulation. Fertil Steril. 1987;47(5):812–5.

    PubMed  CAS  Google Scholar 

  3. Padhy N, Gupta S, Mahla A, Latha M, Varma T. Demographic characteristics and clinical profile of poor responders in IVF/ICSI: a comparative study. J Hum Reprod Sci. 2010;3(2):91–4.

    Article  PubMed  Google Scholar 

  4. Coccia ME, Rizzello F, Mariani G, Bulletti C, Palagiano A, Scarselli G. Impact of endometriosis on in vitro fertilization and embryo transfer cycles in young women: a stage-dependent interference. Acta Obstet Gynecol Scand. 2011;90(11):1232–8.

    Article  PubMed  Google Scholar 

  5. Keay SD, Barlow R, Eley A, Masson GM, Anthony FW, Jenkins JM. The relation between immunoglobulin G antibodies to Chlamydia trachomatis and poor ovarian response to gonadotropin stimulation before in vitro fertilization. Fertil Steril. 1998;70(2):214–8.

    Article  PubMed  CAS  Google Scholar 

  6. Lamazou F, Fuchs F, Grynberg M, Gallot V, Herzog E, Fanchin R, et al. [Cancellation of IVF-ET cycles: poor prognosis, poor responder, or variability of the response to controlled ovarian hyperstimualtion? an analysis of 142 cancellations.]. J Gynecol Obstet Biol Reprod (Paris). 2011. Abstract.

  7. Vollenhoven B, Osianlis T, Catt J. Is there an ideal stimulation regimen for IVF for poor responders and does it change with age? J Assist Reprod Genet. 2008;25(11–12):523–9.

    Article  PubMed  Google Scholar 

  8. Gurgan T, Demirol A. Recombinant luteinizing hormone in assisted reproductive technology. Rev Gynaecol Pract. 2005;5(1):45–50.

    Article  Google Scholar 

  9. Esposito MA, Barnhart KT, Coutifaris C, Patrizio P. Role of periovulatory luteinizing hormone concentrations during assisted reproductive technology cycles stimulated exclusively with recombinant follicle-stimulating hormone. Fertil Steril. 2001;75(3):519–24.

    Article  PubMed  CAS  Google Scholar 

  10. Westergaard LG, Laursen SB, Andersen CY. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod. 2000;15(5):1003–8.

    Article  PubMed  CAS  Google Scholar 

  11. O'Dea L, O'Brien F, Currie K, Hemsey G. Follicular development induced by recombinant luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in anovulatory women with LH and FSH deficiency: evidence of a threshold effect. Curr Med Res Opin. 2008;24(10):2785–93.

    Article  PubMed  Google Scholar 

  12. Shoham Z, Smith H, Yeko T, O'Brien F, Hemsey G, O'Dea L. Recombinant LH (lutropin alfa) for the treatment of hypogonadotrophic women with profound LH deficiency: a randomized, double-blind, placebo-controlled, proof-of-efficacy study. Clin Endocrinol (Oxf). 2008;69(3):471–8.

    Article  CAS  Google Scholar 

  13. The European Recombinant Human LH Study Group. Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. J Clin Endocrinol Metab. 1998;83(5):1507–14.

    Article  Google Scholar 

  14. Burgues S. The effectiveness and safety of recombinant human LH to support follicular development induced by recombinant human FSH in WHO group I anovulation: evidence from a multicentre study in Spain. Hum Reprod. 2001;16(12):2525–32.

    Article  PubMed  CAS  Google Scholar 

  15. Matorras R, Prieto B, Exposito A, Mendoza R, Crisol L, Herranz P, et al. Mid-follicular LH supplementation in women aged 35–39 years undergoing ICSI cycles: a randomized controlled study. Reprod Biomed Online. 2011;22 Suppl 1:S43–51.

    Article  PubMed  Google Scholar 

  16. Filicori M, Fazleabas AT, Huhtaniemi I, Licht P, Rao Ch V, Tesarik J, et al. Novel concepts of human chorionic gonadotropin: reproductive system interactions and potential in the management of infertility. Fertil Steril. 2005;84(2):275–84.

    Article  PubMed  CAS  Google Scholar 

  17. Filicori M, Cognigni GE, Taraborrelli S, Spettoli D, Ciampaglia W, de Fatis CT, et al. Luteinizing hormone activity supplementation enhances follicle-stimulating hormone efficacy and improves ovulation induction outcome. J Clin Endocrinol Metab. 1999;84(8):2659–63.

    Article  PubMed  CAS  Google Scholar 

  18. Serafini P, Yadid I, Motta EL, Alegretti JR, Fioravanti J, Coslovsky M. Ovarian stimulation with daily late follicular phase administration of low-dose human chorionic gonadotropin for in vitro fertilization: a prospective, randomized trial. Fertil Steril. 2006;86(4):830–8.

    Article  PubMed  CAS  Google Scholar 

  19. Blockeel C, De Vos M, Verpoest W, Stoop D, Haentjens P, Devroey P. Can 200 IU of hCG replace recombinant FSH in the late follicular phase in a GnRH-antagonist cycle? a pilot study. Hum Reprod. 2009;24(11):2910–6.

    Article  PubMed  CAS  Google Scholar 

  20. Kosmas IP, Zikopoulos K, Georgiou I, Paraskevaidis E, Blockeel C, Tournaye H, et al. Low-dose HCG may improve pregnancy rates and lower OHSS in antagonist cycles: a meta-analysis. Reprod Biomed Online. 2009;19(5):619–30.

    Article  PubMed  CAS  Google Scholar 

  21. Filicori M, Cognigni GE, Taraborrelli S, Spettoli D, Ciampaglia W, de Fatis CT. Low-dose human chorionic gonadotropin therapy can improve sensitivity to exogenous follicle-stimulating hormone in patients with secondary amenorrhea. Fertil Steril. 1999;72(6):1118–20.

    Article  PubMed  CAS  Google Scholar 

  22. Berkkanoglu M, Isikoglu M, Aydin D, Ozgur K. Clinical effects of ovulation induction with recombinant follicle-stimulating hormone supplemented with recombinant luteinizing hormone or low-dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders. Fertil Steril. 2007;88(3):665–9.

    Article  PubMed  CAS  Google Scholar 

  23. Chung K, Krey L, Katz J, Noyes N. Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists. Fertil Steril. 2005;84(2):313–8.

    Article  PubMed  CAS  Google Scholar 

  24. Griesinger G, Schultze-Mosgau A, Dafopoulos K, Schroeder A, Schroer A, von Otte S, et al. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol. Hum Reprod. 2005;20(5):1200–6.

    Article  PubMed  CAS  Google Scholar 

  25. Fabregues F, Creus M, Penarrubia J, Manau D, Vanrell JA, Balasch J. Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in down-regulated women of advanced reproductive age. Fertil Steril. 2006;85(4):925–31.

    Article  PubMed  CAS  Google Scholar 

  26. World Health Organization. Laboratory manual of the WHO for the examination of human semen and sperm-cervical mucus interaction. Ann Ist Super Sanita. 2001;37(1):I–XII. 1–123.

    Google Scholar 

  27. Veeck LL. Oocyte assessment and biological performance. Ann N Y Acad Sci. 1988;541:259–74.

    Article  PubMed  CAS  Google Scholar 

  28. Rezazadeh Valojerdi M, Eftekhari-Yazdi P, Karimian L, Hassani F, Movaghar B. Vitrification versus slow freezing gives excellent survival, post warming embryo morphology and pregnancy outcomes for human cleaved embryos. J Assist Reprod Genet. 2009;26(6):347–54.

    Article  PubMed  Google Scholar 

  29. Sullivan MW, Stewart-Akers A, Krasnow JS, Berga SL, Zeleznik AJ. Ovarian responses in women to recombinant follicle-stimulating hormone and luteinizing hormone (LH): a role for LH in the final stages of follicular maturation. J Clin Endocrinol Metab. 1999;84(1):228–32.

    Article  PubMed  CAS  Google Scholar 

  30. Campbell BK, Dobson H, Baird DT, Scaramuzzi RJ. Studies on the role of LH in the maturation of the pre-ovulatory follicle in a sheep using a GnRH-antagonist. Anim Reprod Sci. 1997;48(2–4):219–34.

    Article  PubMed  CAS  Google Scholar 

  31. Fleming R, Lloyd F, Herbert M, Fenwick J, Griffiths T, Murdoch A. Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone. Hum Reprod. 1998;13(7):1788–92.

    Article  PubMed  CAS  Google Scholar 

  32. Ferraretti AP, Gianaroli L, Magli MC, D'Angelo A, Farfalli V, Montanaro N. Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. Fertil Steril. 2004;82(6):1521–6.

    Article  PubMed  CAS  Google Scholar 

  33. Drakakis P, Loutradis D, Beloukas A, Sypsa V, Anastasiadou V, Kalofolias G, et al. Early hCG addition to rFSH for ovarian stimulation in IVF provides better results and the cDNA copies of the hCG receptor may be an indicator of successful stimulation. Reprod Biol Endocrinol. 2009;7:110.

    Article  PubMed  Google Scholar 

  34. Filicori M, Cognigni GE, Taraborrelli S, Parmegiani L, Bernardi S, Ciampaglia W. Intracytoplasmic sperm injection pregnancy after low-dose human chorionic gonadotropin alone to support ovarian folliculogenesis. Fertil Steril. 2002;78(2):414–6.

    Article  PubMed  Google Scholar 

  35. Filicori M, Cognigni GE, Gamberini E, Parmegiani L, Troilo E, Roset B. Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation. Fertil Steril. 2005;84(2):394–401.

    Article  PubMed  Google Scholar 

  36. Caglar GS, Asimakopoulos B, Nikolettos N, Diedrich K, Al-Hasani S. Recombinant LH in ovarian stimulation. Reprod Biomed Online. 2005;10(6):774–85.

    Article  PubMed  CAS  Google Scholar 

  37. Humaidan P, Bungum M, Bungum L, Yding Andersen C. Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study. Reprod Biomed Online. 2004;8(6):635–43.

    Article  PubMed  CAS  Google Scholar 

  38. Lisi F, Rinaldi L, Fishel S, Lisi R, Pepe G, Picconeri MG, et al. Use of recombinant FSH and recombinant LH in multiple follicular stimulation for IVF: a preliminary study. Reprod Biomed Online. 2001;3(3):190–4.

    Article  PubMed  CAS  Google Scholar 

  39. Bosch E, Labarta E, Crespo J, Simon C, Remohi J, Pellicer A. Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis. Fertil Steril. 2011;95(3):1031–6.

    Article  PubMed  CAS  Google Scholar 

  40. Ferrari B, Barusi L, Coppola F. Clinical and endocrine effects of ovulation induction with FSH and hCG supplementation in low responders in the midfollicular phase. A pilot study. J Reprod Med. 2002;47(2):137–43.

    PubMed  CAS  Google Scholar 

  41. Laml T, Obruca A, Fischl F, Huber JC. Recombinant luteinizing hormone in ovarian hyperstimulation after stimulation failure in normogonadotropic women. Gynecol Endocrinol. 1999;13(2):98–103.

    Article  PubMed  CAS  Google Scholar 

  42. Loutradis D, Elsheikh A, Kallianidis K, Drakakis P, Stefanidis K, Milingos S, et al. Results of controlled ovarian stimulation for ART in poor responders according to the short protocol using different gonadotrophins combinations. Arch Gynecol Obstet. 2004;270(4):223–6.

    Article  PubMed  CAS  Google Scholar 

  43. Bjercke S, Tanbo T, Abyholm T, Omland A, Opoien HK, Fedorcsak P. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing their first treatment cycle of IVF or ICSI. Acta Obstet Gynecol Scand. 2010;89(8):1053–60.

    Article  PubMed  CAS  Google Scholar 

  44. Hompes PG, Broekmans FJ, Hoozemans DA, Schats R. Effectiveness of highly purified human menopausal gonadotropin vs. recombinant follicle-stimulating hormone in first-cycle in vitro fertilization-intracytoplasmic sperm injection patients. Fertil Steril. 2008;89(6):1685–93.

    Article  PubMed  CAS  Google Scholar 

  45. Koichi K, Yukiko N, Shima K, Sachiko S. Efficacy of low-dose human chorionic gonadotropin (hCG) in a GnRH antagonist protocol. J Assist Reprod Genet. 2006;23(5):223–8.

    Article  PubMed  Google Scholar 

  46. Kolibianakis EM, Kalogeropoulou L, Griesinger G, Papanikolaou EG, Papadimas J, Bontis J, et al. Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? a systematic review and meta-analysis. Hum Reprod Update. 2007;13(5):445–52.

    Article  PubMed  CAS  Google Scholar 

  47. Van Horne AK, Bates Jr GW, Robinson RD, Arthur NJ, Propst AM. Recombinant follicle-stimulating hormone (rFSH) supplemented with low-dose human chorionic gonadotropin compared with rFSH alone for ovarian stimulation for in vitro fertilization. Fertil Steril. 2007;88(4):1010–3.

    Article  PubMed  Google Scholar 

  48. Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L. ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011;26(7):1616–24.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We would like to extend our special thanks to Mrs. Azam Sanati for data entry and all participants involved in this study.

Author information

Authors and Affiliations

  1. Department of Endocrinology and Female Infertility, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, P.O Box:19395-4644, Tehran, Iran

    Tahereh Madani, Ladan Mohammadi Yeganeh & Shabnam Khodabakhshi

  2. Statistics Department, Mathematical Science & Computer Faculty, Shahid Chamran University, Ahwaz, Iran

    Mohammad Reza Akhoond

  3. Department of Embryology, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran

    Fatemeh Hasani

Authors
  1. Tahereh Madani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ladan Mohammadi Yeganeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shabnam Khodabakhshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mohammad Reza Akhoond
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fatemeh Hasani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tahereh Madani.

Additional information

Capsule Adding 100 IU hCG to rFSH in a GnRH agonist cycle in poor responders improve response to stimulation

Rights and permissions

Reprints and permissions

About this article

Cite this article

Madani, T., Mohammadi Yeganeh, L., Khodabakhshi, S. et al. Efficacy of low dose hCG on oocyte maturity for ovarian stimulation in poor responder women undergoing intracytoplasmic sperm injection cycle: a randomized controlled trial. J Assist Reprod Genet 29, 1213–1220 (2012). https://doi.org/10.1007/s10815-012-9854-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10815-012-9854-3

Keywords

Search

Navigation